{"id":"884e2b9f-bd4f-5c5b-b276-fc438273a66d","stable_key":"8b3cf083-ea9c-54f5-b42b-bf1fef5b2978:metformin-neuropathy-severity","predicate":"associated_with","statement":"Clinical and electrophysiological measures identified more severe peripheral neuropathy in metformin-treated patients, and the cumulative metformin dose correlated strongly with these differences.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"39ebc101-1af0-5f03-95e3-a34230b375e5","mechanism_event_label":"More drug over time went with worse nerve findings in this comparison.","subject":{"id":"519971b1-5aef-5ad7-8022-840144855cd0","slug":"metformin","display_name":"Metformin","entity_type_key":"drug"},"object":{"id":"fd60b638-44a9-5644-9de9-d0afbd881c2e","slug":"diabetic-peripheral-neuropathy-severity","display_name":"Clinical and electrophysiological severity of diabetic peripheral neuropathy","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"39ebc101-1af0-5f03-95e3-a34230b375e5","stable_key":"8b3cf083-ea9c-54f5-b42b-bf1fef5b2978:metformin-neuropathy-severity-event","event_type":"observed_intervention","label":"More drug over time went with worse nerve findings in this comparison.","description":"Clinical and electrophysiological measures identified more severe peripheral neuropathy in metformin-treated patients, and the cumulative metformin dose correlated strongly with these differences.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"519971b1-5aef-5ad7-8022-840144855cd0","slug":"metformin","display_name":"Metformin","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"fd60b638-44a9-5644-9de9-d0afbd881c2e","slug":"diabetic-peripheral-neuropathy-severity","display_name":"Clinical and electrophysiological severity of diabetic peripheral neuropathy","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/metformin-research/19846797.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"801079bb07e94e223a1d7bd7fc99c9f229320aa56b6afa11700765f481558b33\", \"start_char\": 0, \"end_char\": 1789, \"text_sha256\": \"801079bb07e94e223a1d7bd7fc99c9f229320aa56b6afa11700765f481558b33\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Prospective case-control study of 122 people with type 2 diabetes and symptomatic neuropathy","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"More than six months of metformin versus no metformin exposure","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Case-control design with nerve conduction studies. Cumulative dose correlated with severity, but the design cannot establish that the drug caused the neuropathy.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake.","comparator":null,"unit":null,"notes":"","entity":{"slug":"metformin","display_name":"Metformin","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"More drug over time went with worse nerve findings in this comparison.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[metformin-p19846797] Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. (2010). https://pubmed.ncbi.nlm.nih.gov/19846797/ DOI: 10.2337/dc09-0606","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Peripheral nerve","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"764890a9-30f7-56db-8cda-a50f1545cacc","evidence_kind":"source_excerpt","locator":"Lines 1217-1228","start_line":1217,"end_line":1228,"excerpt":"### metformin-neuropathy-severity\nClinical and electrophysiological measures identified more severe peripheral neuropathy in metformin-treated patients, and the cumulative metformin dose correlated strongly with these differences.\nCondition category: biomarker_context\nnutrient_topic: Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake.\nplain_language: More drug over time went with worse nerve findings in this comparison.\norganism: Human\ntissue_or_cell_type: Peripheral nerve\nexperimental_model: Prospective case-control study of 122 people with type 2 diabetes and symptomatic neuropathy\nlimitations: Case-control design with nerve conduction studies. Cumulative dose correlated with severity, but the design cannot establish that the drug caused the neuropathy.\nexposure: More than six months of metformin versus no metformin exposure\nevidence_span: {\"source_cache\": \"artifacts/metformin-research/19846797.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"801079bb07e94e223a1d7bd7fc99c9f229320aa56b6afa11700765f481558b33\", \"start_char\": 0, \"end_char\": 1789, \"text_sha256\": \"801079bb07e94e223a1d7bd7fc99c9f229320aa56b6afa11700765f481558b33\"}\n[metformin-p19846797] Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. (2010). https://pubmed.ncbi.nlm.nih.gov/19846797/ DOI: 10.2337/dc09-0606","model_system":"Prospective case-control study of 122 people with type 2 diabetes and symptomatic neuropathy","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [metformin-p19846797] Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. (2010). https://pubmed.ncbi.nlm.nih.gov/19846797/ DOI: 10.2337/dc09-0606","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"d0474bd9-7cfd-5695-a152-12f3633a6813","stable_key":"import-8b3cf083-ea9c-54f5-b42b-bf1fef5b2978","title":"Metformin: transport, molecular targets, gut mechanisms and nutrient interactions (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"0b51d0759aeeb88ac5b3a6277245a196b2bb024d7c32ec89379ed428fb06bfb5","revision_id":"0405c75e-f06e-5af7-a642-1777802f6004","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}